Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Pureland Global Venture (PGV) is a private investment group based in Singapore, founded in 2014 as part of the broader Pureland Group. The firm operates as a direct investment fund with a focus on impact investments in the medical technology sector. PGV targets early-stage companies that enhance patient care and address healthcare supply and demand gaps, primarily in the Asia-Pacific region, India, and the United States.
As of now, Pureland Global Venture employs a team of 12 professionals and has established itself as a significant player in the medical technology investment space. The firm has a dual fund structure, with Fund I focusing on secondary markets and capital preservation, while Fund II is dedicated to impact-driven venture capital investments in medtech. The firm has received institutional endorsement as a co-investment partner from Enterprise Singapore, enhancing its credibility in the startup ecosystem.
Pureland Global Venture specializes in investments within the medical technology sector, particularly in AI solutions and medical devices. The firm emphasizes affordability and effectiveness, aiming to improve clinical efficiency and provide innovative therapeutic solutions tailored for emerging markets. PGV does not engage in investments related to biomedical sciences or pharmaceutical drug discovery startups.
The firm primarily invests in early-stage companies, focusing on seed to Series A rounds. Its geographic focus includes the Asia-Pacific region, India, the United States, and Europe. PGV seeks startups that can demonstrate a clear impact on patient care and operational efficiency, aligning with its mission to enhance healthcare access and quality.
Pureland Global Venture has a diverse portfolio that spans over ten sectors globally, although specific portfolio companies are not fully enumerated. Notable investments include:
Portfolio companies are backed by prestigious organizations, including the Gates Foundation, Stanford University, and the American College of Cardiology. The firm’s investments cover various therapeutic areas such as oncology, ophthalmology, brain health, orthopedics, cardiology, and chronic disease management, reflecting its commitment to improving healthcare outcomes.
Mark Wang - Partner. Mark has a background in venture capital and has been instrumental in shaping PGV's investment strategy. His expertise lies in identifying impactful medical technology ventures.
Other team members include Mr. Eiffel Sun, Mr. Hong Shaoming, Mr. Rayson Tan, and Mr. Zhang Heng, who collectively bring diverse experience in healthcare and technology sectors.
To pitch to Pureland Global Venture, founders should use the email address sasha.zeng@purelandventure.com. It is important to include a comprehensive deck that outlines the business model, market opportunity, and the impact of the solution on patient care. Response times may vary, but founders should expect a thorough review process.
In 2021, Pureland Global Venture participated in a GBP 18.45M Series B funding round for Leo Cancer Care, which focuses on upright radiotherapy solutions. Additionally, the firm invested in One Health Group, which raised $1.5M for health analytics.
PGV continues to expand its influence in the medical technology sector, leveraging its partnerships with organizations such as the Gates Foundation and Stanford University to enhance its portfolio's impact.
What are Pureland Global Venture's investment criteria?
Pureland Global Venture focuses on early-stage medical technology companies that enhance patient care and address healthcare gaps. The firm specifically looks for ventures in AI solutions and medical devices that demonstrate affordability and effectiveness in emerging markets.
How can I apply or pitch to Pureland Global Venture?
Founders can pitch their ideas by reaching out via email at sasha.zeng@purelandventure.com. It is advisable to include a detailed deck outlining the business model, market opportunity, and impact on patient care.
What makes Pureland Global Venture different from other investors?
PGV distinguishes itself through its impact-driven investment strategy, focusing solely on medical technology that improves clinical efficiency and patient outcomes. The firm also has a strong institutional backing from Enterprise Singapore, enhancing its credibility.
What is the geographic scope of Pureland Global Venture's investments?
The firm primarily invests in the Asia-Pacific region, India, the United States, and Europe, with a significant portion of its portfolio allocated to the US market.
What is the typical check size for investments?
While specific check sizes are not disclosed, Pureland Global Venture typically invests in seed to Series A rounds, which generally range from hundreds of thousands to several million dollars.
What kind of post-investment involvement does Pureland Global Venture have?
PGV adds value to its portfolio companies by providing operational support, strategic guidance, and leveraging its expertise in medical technology to enhance clinical workflows and market relevance.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.